1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
60EE96B55C58429DF6525790900408D5A
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/0EE96B55C58429DF6525790900408D5A!OpenDocument
18
19OpenDocument
2018.97.9.174
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Product Launch » Market Entry and Oncology

Complimentary Excerpt: Payer Factors that Shape a Successful Oncology Market Entry: Education and Access Insights

DB Image

Excerpt in Cart

ID: MD-266


Features:

Metrics, Graphics


Pages/Slides: 4


Published: Pre-2020


Delivery Format: Online PDF Document


 

License Options:


Download FREE Excerpt

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER

To download this excerpt, click "
Download Free Excerpt".


To return to the study abstract to purchase the full study
- click here

This excerpt includes research findings and metrics from document #5152 "Payer Factors that Shape a Successful Oncology Market Entry: Education and Access Insights"


Industries Profiled:
Pharmaceutical; Medical Device; Biotech; Health Care; Chemical; Manufacturing; Diagnostic; Consumer Products; Media


Companies Profiled:
GlaxoSmithKline; Bristol-Myers Squibb; Roche; Lilly; Novartis; Merck; AstraZeneca; Genentech; Phillips; TGC MedTech; MedImmune; Abbott; Amgen; Bayer; Actelion; Cephalon; Inc.; Teva Neuroscience; Novo Nordisk; Amylin; Laboratorios Deramtologicos Darier; IDS Canada; UCB Pharma; Bayer Schering Pharma; Quintiles; MerckSerono; Servier; Ther-Rx; ProCaps Laboratories; Baxter Healthcare; Urologix; Synapse biomedical; Talecris; NicOx; Eisai; Direct Supply; Shire; ChemGenex Pharmaceuticals; Takeda Pharmaceuticals

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.